Introduction: Treatment of cancers of paranasal sinuses poses important challenges to the head and neck surgeons, radiation and medical oncologists. This study presents treatment outcome in 33 patients, who were retrospectively treated between 2000 and 2007. Materials and Methods: The records of 33 patients (17 men and 16 women) with maxillary sinus squamous or adenocarcinoma treated with curative intent at Clinical Oncology and Nuclear Medicine Department, Mansoura University were analyzed. Patient›s age ranged from 24 to 85 years (median 50 years). Most tumors were locally advanced at presentation. All patients underwent conventional radiotherapy (RT), combined with surgery in 89% and 58%, received chemotherapy.
INTRODUCTION
Cancers of the paranasal sinuses (PNSs) are uncommon, account about 3% of aerodigestive malignancies 1 . Their treatment poses important challenges to the head and neck surgeons, radiation and medical oncologists [2] [3] [4] [5] . They are associated with suboptimal outcomes and significant tumor and treatment -associated morbidity [4] [5] [6] [7] [8] [9] [10] [11] . PNSs often present in advanced stages. The complex anatomy and the close proximity of critical structures compromise effectual surgical excision and radiation deliverance 2, 12, 13 . Substantial uncertainty surrounds their fundamental aspects of treatment, hence the optimal therapy remains to be defined 14 .
The purpose of this paper is to present the experience in the management of patients with maxillary sinus carcinoma treated with curative intent at Clinical Oncology and Nuclear Medicine Department, Mansoura University.
MATERIALS AND METHODS
The medical records of 33 patients with the diagnosis of maxillary sinus carcinoma treated with curative intent between 2000 to 2008 were reviewed.
There were 17 males and 16 females. The median age was 50 years (range 24-85 years). The most common presenting symptom was facial swelling (61%), followed by pain (39%), nasal obstruction (27%), epistaxis (15%) and crainial nerve neuropathy (12%). Facial edema and symptoms of sinusitis, each was present in 1 (3%) patient.
The diagnostic evaluation at presentation included a complete physical examination and CT/or MRI of the sinuses and brain. All patients were restaged retrospectively according to the 2002 American Joint Committee on Cancer Staging System (AJCC) for maxillary sinus tumors 15 . The majority of patients presented with advanced stage (III and IV, 82%). Nodal disease at presentation was seen in 2 patients. One patient had N1 and the other had N2 disease. No patient had distant metastases at time of diagnosis.
All patients had biopsy-proven squamous cell (79%) or adenocarcinoma (21%) of maxillary sinus. Differentiation of histologic subtypes was available in 23 of 33 patients; the tumor was well differentiated in 5 patients, moderately differentiated in 7 patients and poorly differentiated in 11 patients. All the 33 patients were treated with a curative intent. Twenty-nine (88%) patients were treated with surgery followed by postoperative radiotherapy. The surgical extent ranged from radical maxillectomy in 2 (6%) patients, to total maxillectomy in 20 (61%), partial maxillectomy in 7 (21%) and 4 (12%) patients underwent biopsy only. Negative resection margins were achieved in 3 (9%) patients and 6 (18%) had positive margin, while margin status was unknown in 24 (73%) patients in postoperative microscopic examination. Two (6%) patients underwent a neck dissection. Nineteen (77%) patients received chemotherapy, of them 10 (30%) underwent adjuvant therapy, while 9 (27%) received concurrent radiotherapy and chemotherapy. The agents used included cisplatinum and 5-flurouracil. Radical RT alone was offered in 4 (12%) patients (Table 2 ). All patients underwent radiotherapy using 60Co -rays or 6-MV X-rays. Patients were treated using either a twoor three field, wedge pair arrangement. The median dose to the primary site for patients receiving postoperative RT was 5000 cGy; for those receiving RT alone and concurrent CT and RT it was 6000 cGy. The regional nodes were only treated in patients with neck node involvement. Statistical Analysis: Overall survival and disease free survival were calculated using the Kaplan -Meier method. These end points were determined from the date of diagnosis until the event of death for survival and local or regional failure for disease free survival.
RESULTS
After a median follow up of 18 months (range 4-90), 11 (33%) patients were alive at time of analysis; of these 9 (27%) had no clinical evidence of disease. Twenty two patients (67%) had died during the evaluation period, 14 (42%) as a result of recurrent or persistent primary tumor, 4 (12%) of treatment complications, 3 (9%) of other causes without evidence of disease. The cause of death was unknown in 1 (3%) patient. The majority of recurrences were within 1 year of diagnosis.
Out of the 33 patients, 16 (48%) relapsed. Fourteen (42%) patients experienced local recurrence, while 6 (18%) had regional recurrence. Isolated local and neck relapse were demonstrated in 10 and 2 patients, respectively. Isolated local failure was the most common pattern of recurrence (Table 3) .
Recurrence was demonstrated in 13 out of 26 (50%) patients with SCC and in 3 out of 7 (43%) patients with adenocarcinoma histopathology. Surgery was done in 29 patients. Fifty three percent of patients who received PORT + CT failed treatment while 20% of those received PORT only experienced relapse. All patients who received RRT relapsed (Table 3) .
DISCUSSION
The patient distribution in the present study was consistent with other publications ; males are more commonly affected than females, most patients present with locally advanced tumors; 82% of our patients presented with T3 or T4 disease.
The presenting signs and symptoms result from invasion of the surrounding critical structures. In a series of 106 patients, Blanco et al. 3 described pain in 43%, nasal obstruction in 36%, cranial neuropathy in 26%, epistaxis in 24% and sinusitis in 14% of the cases. The presentation was similar in our patients with mass (61%) pain (39%), nasal obstruction (27%), epistaxis (15%) and crainial neuropathy (12%) as the most common presenting clinical features. Clinically positive cervical metastases were present in 6% of patients in the present series. This is in keeping with the 4-15% incidence of adenopathy noted in the literature 11, [16] [17] [18] [19] [20] .
The majority of literature supports the contention that surgery and radiotherapy in combination is the most significant mode of treatment of maxillary sinus carcinoma because this approach has demonstrated superior outcomes. This was evident in this study.
Blanco et al. 3 in 106 patients noted a statistically significant improvement in the disease free survival in the patients receiving combined modality treatment compared to those receiving radiotherapy alone (35% VS 29%; P<0.05). Qureshi et al. 16 reported 5-year overall survival of 42% after combined modality therapy (CMT). Hoppe 21 reported 5-year DFS and OS of 55% and 67%, respectively in 85 patients with PNS cancers treated with post-op RT (62% treated with IMRT or 3-D-CRT, rest with 2D). Daly et al. 22 reported on 36 patients with PNS cancers, 32 after gross total resection. They were treated with IMRT. The 5-year local control, DFS and OS rates were 58%, 55% and 45%, respectively. Radiotherapy-related complications occurred in 7 patients (21%) and included brain necrosis, conjunctivitis, oromaxillary fistula, persistent mucositis, trismus and blindness (Table 4 ). The 3 and 5-year overall survival of the 33 patients was 36% and 33%, respectively (Figure 1) . The 3 and 5-year disease free survival was 36% and 27%, respectively (Figure 2 ). Dirix et al. 23 reported actuarial 5-year OS and DFS rates of 54% and 37%, respectively for 127 patients with cancer of the PNSs or nasal cavity who were treated with preoperative or postoperative primary RT, using conventional or 3D-CRT. However Dulguerov et al. 24 demonstrated a progressive improvement in outcomes for all treatment modalities (surgery, surgery + radiotherapy and radiotherapy) during the past 4 decades.
Local failure remains the dominant cause of poor outcome in this tumor 2, 12, 13 . Pattern of failure in the present series revealed that 42% of patients failed at the primary site. Although our treatment outcomes lie within the published range for maxillary sinus carcinoma treated with surgery and conventional RT [2] [3] [4] 16, 25 , strategies for improving local control are needed for the management of this disease. Tiwari et al. 18 have recommended a mandibulotomy for better clearance of the infratemporal fossa. Although, long-term results are awaited, the clearance with this approach seems to be encouraging.
The addition of neoadjuvant CT has been advocated for locally advanced PNSs carcinoma and has been shown to be beneficial in a selected number of patients. In one series 92% DFS was reported at a follow-up of 55 months following neoadjuvant chemotherapy 26 . Similarly, use of preoperative radiotherapy with concomitant intra-arterial chemotherapy has been reported 27 .
Samant 27 treated 18 patients (84% T4 lesions) with preoperative high dose intra-arterial cisplatin + IV thiosulfate with concurrent RT (50Gy). Surgery was planned 8 wks post RT (organ sparing, if possible). A 2-yr OS of 68% and 5-yr OS of 53% were reported. However larger studies are needed to confirm these results 2, 12, 28, 29 .
In this study 6 out of 33 patients had disease failure in the cervical lymph nodes. The role of elective neck treatment is also debatable. Some authors recommend prophylactic ipsilateral neck irradiation based on their findings of more than 25% incidence of neck failure and high risk distant metastases and poor survival 4, 11, 20 . Other authors do not favor ipsilateral neck treatment 14, 18 .
In this study histological type had no influence on the clinical outcome. This was reported by others 30 .
Treatment of PNSs cancer is often associated with significant late toxicity. Two of our patients (6%) developed unilateral blindness. Other investigators [31] [32] [33] have reported higher rates of unilateral and bilateral blindness, exceeding 60% and 10%, respectively, suggesting an increased incidence of late complications with long-term evaluation. In light of such high incidence of late sequelae, attempts to minimize toxicity with conformal RT21 or IMRT 21, 22 techniques seem reasonable. Weber 34 reported acceptable ophthalmologic complications using accelerated fractionated RT for advanced sinonasal malignancies employing photons/ protons. Other treatment complications experienced by patients in this study were brain necrosis (3%), conjunctivitis (3%) oromaxillary fistula (3%), persistent mucositis (3%) and trismus (3%). The incidence rates were higher than that reported by Blanco et al. 3 . This may be attributed to that 11% of their patients were treated with 3D-CRT or IMRT.
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CONCLUSION
The present study indicates that the majority of our patients presented with advanced disease, resulting in poor outcomes to conventional treatment modalities. Locoregional disease progression remains a significant pattern of failure. New approaches such as neoadjuvant or concomitant chemoradiotherapy with aggressive surgery need to be considered and evaluated in prospective studies.
